Diagonal Bio AB (publ) (DIABIO.ST)
SEK 0.01
(0.0%)
SEK 0.01
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 14.7 Million SEK | -14.62% |
| 2022 | 17.21 Million SEK | 48.7% |
| 2021 | 11.57 Million SEK | 1535.31% |
| 2020 | 708 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.76 Million SEK | -7.15% |
| 2024 Q3 | 928 Thousand SEK | -66.43% |
| 2024 Q1 | 2.97 Million SEK | 3.58% |
| 2023 Q2 | 3.7 Million SEK | 0.0% |
| 2023 FY | 14.7 Million SEK | -14.62% |
| 2023 Q4 | 2.87 Million SEK | -15.32% |
| 2023 Q1 | 3.7 Million SEK | -11.31% |
| 2023 Q3 | 3.39 Million SEK | -8.3% |
| 2022 FY | 17.21 Million SEK | 48.7% |
| 2022 Q4 | 4.17 Million SEK | -5.35% |
| 2022 Q3 | 4.4 Million SEK | -8.92% |
| 2022 Q2 | 4.84 Million SEK | 27.63% |
| 2022 Q1 | 3.79 Million SEK | 8.59% |
| 2021 Q2 | 3.06 Million SEK | 320.91% |
| 2021 FY | 11.57 Million SEK | 1535.31% |
| 2021 Q3 | 4.29 Million SEK | 40.49% |
| 2021 Q4 | 3.49 Million SEK | -18.75% |
| 2021 Q1 | 727 Thousand SEK | 127.19% |
| 2020 Q4 | 320 Thousand SEK | 125.35% |
| 2020 Q2 | 245 Thousand SEK | 3400.0% |
| 2020 Q1 | 7000.00 SEK | 0.0% |
| 2020 FY | 708 Thousand SEK | 0.0% |
| 2020 Q3 | 142 Thousand SEK | -42.04% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Simris Alg AB (publ) | 38.64 Million SEK | 61.958% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 95.428% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 95.89% |
| Xintela AB (publ) | 57.31 Million SEK | 74.353% |
| Active Biotech AB (publ) | 44.8 Million SEK | 67.194% |
| Amniotics AB (publ) | 29.07 Million SEK | 49.436% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -0.321% |
| BioArctic AB (publ) | 89.62 Million SEK | 83.599% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 99.029% |
| Camurus AB (publ) | 1.05 Billion SEK | 98.613% |
| Cantargia AB (publ) | 290.01 Million SEK | 94.931% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 32.861% |
| CombiGene AB (publ) | 44.14 Million SEK | 66.7% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 89.719% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 48.105% |
| Genovis AB (publ.) | 88.19 Million SEK | 83.333% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 87.226% |
| Mendus AB (publ) | 129.13 Million SEK | 88.617% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -102.256% |
| Intervacc AB (publ) | 79.78 Million SEK | 81.575% |
| Kancera AB (publ) | 63.07 Million SEK | 76.695% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -166.353% |
| LIDDS AB (publ) | 27.75 Million SEK | 47.031% |
| Lipum AB (publ) | 37.3 Million SEK | 60.597% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -102.647% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 89.184% |
| NextCell Pharma AB | -576.01 Thousand SEK | 2651.999% |
| OncoZenge AB (publ) | 15.9 Million SEK | 7.576% |
| Saniona AB (publ) | 1.07 Million SEK | -1264.903% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 91.911% |
| Ziccum AB (publ) | 27.87 Million SEK | 47.27% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | 10.371% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 95.213% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 65.519% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | 16.869% |
| Corline Biomedical AB | 30.16 Million SEK | 51.273% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 74.669% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 82.325% |
| Aptahem AB (publ) | 10.01 Million SEK | -46.81% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 89.086% |
| Fluicell AB (publ) | 28.61 Million SEK | 48.632% |
| Biovica International AB (publ) | 133.72 Million SEK | 89.007% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | 25.72% |
| AcouSort AB (publ) | 25.87 Million SEK | 43.191% |
| Abliva AB (publ) | 27.86 Million SEK | 47.248% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 92.403% |
| 2cureX AB (publ) | 36.51 Million SEK | 59.746% |
| I-Tech AB | 40.14 Million SEK | 63.385% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 98.29% |
| Cyxone AB (publ) | 28.21 Million SEK | 47.898% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 86.559% |
| Biosergen AB | 26.8 Million SEK | 45.168% |
| Nanologica AB (publ) | 69.88 Million SEK | 78.966% |
| SynAct Pharma AB | 224.49 Million SEK | 93.452% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 66.724% |
| BioInvent International AB (publ) | 441.4 Million SEK | 96.67% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 38.633% |
| Alzinova AB (publ) | 36.39 Million SEK | 59.611% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 94.927% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -87.112% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 86.746% |